title: A comparative study of 201Tl scintigraphy and three-phase bone scintigraphy following therapy in patients with bone and soft-tissue tumors.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the usefulness of 201Tl scintigraphy in comparison with three-phase bone scintigraphy in the differentiation of residual/recurrent tumors from post-therapeutic changes, in patients previously treated for bone and soft-tissue tumors.
  
  
  METHODS
  Thirty-five 201Tl and three-phase bone scintigraphy scans were obtained for 30 patients with a history of bone or soft-tissue tumor who had undergone chemotherapy, radiation therapy, tumor resection, or a combination of these treatments. The planar 201Tl images were acquired 10 mins (early) and 2 hrs (delayed) after the intravenous injection of 111 MBq 201Tl-chloride. Three-phase bone scintigraphy was performed using 740 MBq 99mTc-HMDP at the same lesion site as for 201Tl imaging. The blood flow images were obtained every 10 sec for 2 mins and were immediately followed by the blood pool image after 5 mins. Three to 4 hrs later, bone images were obtained. 201Tl and three-phase bone scintigraphies were correlated with the histopathologic findings and/or clinical follow-up of more than 3 months.
  
  
  RESULTS
  Of the 35 cases, 15 were free of disease and 20 had residual or recurrent tumors. Of the 20 residual or recurrent cases, all had true-positive 201Tl early and delayed scans, while bone scintigraphy was true-positive on the blood flow, blood pool and bone images in 16, 18 and 12 cases, respectively. 201Tl early and delayed images and 99mTc-HMDP blood flow and blood pool images were false-positive in one patient. The histology of this false-positive case showed the presence of lymph proliferative tissue.
  
  
  CONCLUSIONS
  Although 201Tl uptake after treatment does not always indicate recurrence, 201Tl scintigraphy may still be more useful than three-phase bone scintigraphy in the follow-up of patients with bone and soft-tissue tumors following therapy.
authors.affiliation: Department of Radiology, Faculty of Medicine, Kagawa University, Kita-gun, Japan. nisiyosi@kms.ac.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishiyama
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Koiku
authors.initials: K
authors.lastname: Yokoe
authors.forename: Yoji
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Toyama
authors.forename: Katashi
authors.initials: K
authors.lastname: Satoh
authors.forename: Motoomi
authors.initials: M
authors.lastname: Ohkawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000517:prevention & control; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives*; D013793:Thallium; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; C027549:thallium chloride; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D013793:Thallium; D013669:Technetium Tc 99m Medronate